Diagnosis of Serious Conditions Delayed in Association with Ondansetron Treatment for Vomiting in the Pediatric Emergency Department
Objectives We evaluated the characteristics and sought risk factors for hospitalization in children who return to the emergency department within 7 days of discharge after oral or intravenous ondansetron treatment for vomiting. The secondary aim was to determine whether the diagnosis of any serious...
Gespeichert in:
Veröffentlicht in: | Paediatric drugs 2023-03, Vol.25 (2), p.233-238 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 238 |
---|---|
container_issue | 2 |
container_start_page | 233 |
container_title | Paediatric drugs |
container_volume | 25 |
creator | Palnizky Soffer, Gili Schnapp, Zeev Miroluz, Dana Rimon, Ayelet |
description | Objectives
We evaluated the characteristics and sought risk factors for hospitalization in children who return to the emergency department within 7 days of discharge after oral or intravenous ondansetron treatment for vomiting. The secondary aim was to determine whether the diagnosis of any serious condition had been delayed as the result of discharge after ondansetron treatment.
Methods
This retrospective analysis of the medical records of children who had been treated for vomiting with ondansetron in a tertiary care pediatric emergency department and revisited the emergency department within 7 days was performed between 2017 and 2019. We compared demographic and clinical features as well as management between hospitalized and discharged patients, focusing upon potentially delayed diagnoses of serious conditions.
Results
Fifty of the 89 ondansetron-treated children (56.2%) who revisited the emergency department were discharged home after their second emergency department visit and the remaining 39 (43.8%) were hospitalized. No parameter of the management of the first visit was predictive of the outcome of the revisit. Five revisit patients (5.6%) were newly diagnosed with a serious condition, with intussusception and ovarian torsion being the most substantial time-sensitive delays (the other diagnoses were pneumonia and aseptic meningitis).
Conclusions
Physicians assessing patients who had been treated with ondansetron as supportive care for vomiting at an earlier visit to the pediatric emergency department should consider alternative diagnoses despite initial clinical improvement. No definitive risk factor for readmission was identified, but a high level of alertness to a possible meningeal or acute abdominal source is imperative. |
doi_str_mv | 10.1007/s40272-022-00556-5 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2777434187</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2777434187</sourcerecordid><originalsourceid>FETCH-LOGICAL-c300t-6c73e5c474f56d16e981c22600fa79773a436bdeee86a011ad07a78dc5b98f413</originalsourceid><addsrcrecordid>eNp9kM1uGyEURlHVqPlpX6CLCqnrSS8wwMwyctwmUqREStotwnDHIcqAC2NF3ufBg-003WWBQJfvfFc6hHxlcMoA9I_SAte8AV4PSKka-YEcMab7hgPrP-7ebSM73R2S41IeAJgWin8ih0KpXgGXR-T5PNhlTCUUmgZ6izmkdaGzFH2YQoqFnuOj3aCnIdKzUpILdjunT2G6p9fR21hwynVwl9FOI8aJDinTP2msfFxuseke6Q36Cubg6HzEvMToNrV5ZfMO-UwOBvtY8MvrfUJ-_5zfzS6aq-tfl7Ozq8YJgKlRTguUrtXtIJVnCvuOOc4VwGB1r7WwrVALj4idssCY9aCt7ryTi74bWiZOyPd97yqnv2ssk3lI6xzrSsO11q1oWadriu9TLqdSMg5mlcNo88YwMFvxZi_eVPFmJ97ICn17rV4vRvRvyD_TNSD2gVK_4hLz_93v1L4Ax6qP9g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2777434187</pqid></control><display><type>article</type><title>Diagnosis of Serious Conditions Delayed in Association with Ondansetron Treatment for Vomiting in the Pediatric Emergency Department</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Palnizky Soffer, Gili ; Schnapp, Zeev ; Miroluz, Dana ; Rimon, Ayelet</creator><creatorcontrib>Palnizky Soffer, Gili ; Schnapp, Zeev ; Miroluz, Dana ; Rimon, Ayelet</creatorcontrib><description>Objectives
We evaluated the characteristics and sought risk factors for hospitalization in children who return to the emergency department within 7 days of discharge after oral or intravenous ondansetron treatment for vomiting. The secondary aim was to determine whether the diagnosis of any serious condition had been delayed as the result of discharge after ondansetron treatment.
Methods
This retrospective analysis of the medical records of children who had been treated for vomiting with ondansetron in a tertiary care pediatric emergency department and revisited the emergency department within 7 days was performed between 2017 and 2019. We compared demographic and clinical features as well as management between hospitalized and discharged patients, focusing upon potentially delayed diagnoses of serious conditions.
Results
Fifty of the 89 ondansetron-treated children (56.2%) who revisited the emergency department were discharged home after their second emergency department visit and the remaining 39 (43.8%) were hospitalized. No parameter of the management of the first visit was predictive of the outcome of the revisit. Five revisit patients (5.6%) were newly diagnosed with a serious condition, with intussusception and ovarian torsion being the most substantial time-sensitive delays (the other diagnoses were pneumonia and aseptic meningitis).
Conclusions
Physicians assessing patients who had been treated with ondansetron as supportive care for vomiting at an earlier visit to the pediatric emergency department should consider alternative diagnoses despite initial clinical improvement. No definitive risk factor for readmission was identified, but a high level of alertness to a possible meningeal or acute abdominal source is imperative.</description><identifier>ISSN: 1174-5878</identifier><identifier>EISSN: 1179-2019</identifier><identifier>DOI: 10.1007/s40272-022-00556-5</identifier><identifier>PMID: 36696025</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Abdomen ; Antiemetics ; Antiemetics - therapeutic use ; Child ; Children & youth ; Emergency medical care ; Emergency Service, Hospital ; Gastroenteritis ; Hospitalization ; Hospitals ; Humans ; Internal Medicine ; Intestinal obstruction ; Medical records ; Medicine ; Medicine & Public Health ; Meningitis ; Ondansetron - adverse effects ; Original Research Article ; Ovaries ; Patients ; Pediatrics ; Pharmacotherapy ; Physicians ; Pneumonia ; Regression analysis ; Retrospective Studies ; Risk factors ; Vomiting ; Vomiting - drug therapy ; Vomiting - etiology</subject><ispartof>Paediatric drugs, 2023-03, Vol.25 (2), p.233-238</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</rights><rights>Copyright Springer Nature B.V. Mar 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c300t-6c73e5c474f56d16e981c22600fa79773a436bdeee86a011ad07a78dc5b98f413</cites><orcidid>0000-0001-9706-5721</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40272-022-00556-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40272-022-00556-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36696025$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Palnizky Soffer, Gili</creatorcontrib><creatorcontrib>Schnapp, Zeev</creatorcontrib><creatorcontrib>Miroluz, Dana</creatorcontrib><creatorcontrib>Rimon, Ayelet</creatorcontrib><title>Diagnosis of Serious Conditions Delayed in Association with Ondansetron Treatment for Vomiting in the Pediatric Emergency Department</title><title>Paediatric drugs</title><addtitle>Pediatr Drugs</addtitle><addtitle>Paediatr Drugs</addtitle><description>Objectives
We evaluated the characteristics and sought risk factors for hospitalization in children who return to the emergency department within 7 days of discharge after oral or intravenous ondansetron treatment for vomiting. The secondary aim was to determine whether the diagnosis of any serious condition had been delayed as the result of discharge after ondansetron treatment.
Methods
This retrospective analysis of the medical records of children who had been treated for vomiting with ondansetron in a tertiary care pediatric emergency department and revisited the emergency department within 7 days was performed between 2017 and 2019. We compared demographic and clinical features as well as management between hospitalized and discharged patients, focusing upon potentially delayed diagnoses of serious conditions.
Results
Fifty of the 89 ondansetron-treated children (56.2%) who revisited the emergency department were discharged home after their second emergency department visit and the remaining 39 (43.8%) were hospitalized. No parameter of the management of the first visit was predictive of the outcome of the revisit. Five revisit patients (5.6%) were newly diagnosed with a serious condition, with intussusception and ovarian torsion being the most substantial time-sensitive delays (the other diagnoses were pneumonia and aseptic meningitis).
Conclusions
Physicians assessing patients who had been treated with ondansetron as supportive care for vomiting at an earlier visit to the pediatric emergency department should consider alternative diagnoses despite initial clinical improvement. No definitive risk factor for readmission was identified, but a high level of alertness to a possible meningeal or acute abdominal source is imperative.</description><subject>Abdomen</subject><subject>Antiemetics</subject><subject>Antiemetics - therapeutic use</subject><subject>Child</subject><subject>Children & youth</subject><subject>Emergency medical care</subject><subject>Emergency Service, Hospital</subject><subject>Gastroenteritis</subject><subject>Hospitalization</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Intestinal obstruction</subject><subject>Medical records</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meningitis</subject><subject>Ondansetron - adverse effects</subject><subject>Original Research Article</subject><subject>Ovaries</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Pharmacotherapy</subject><subject>Physicians</subject><subject>Pneumonia</subject><subject>Regression analysis</subject><subject>Retrospective Studies</subject><subject>Risk factors</subject><subject>Vomiting</subject><subject>Vomiting - drug therapy</subject><subject>Vomiting - etiology</subject><issn>1174-5878</issn><issn>1179-2019</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kM1uGyEURlHVqPlpX6CLCqnrSS8wwMwyctwmUqREStotwnDHIcqAC2NF3ufBg-003WWBQJfvfFc6hHxlcMoA9I_SAte8AV4PSKka-YEcMab7hgPrP-7ebSM73R2S41IeAJgWin8ih0KpXgGXR-T5PNhlTCUUmgZ6izmkdaGzFH2YQoqFnuOj3aCnIdKzUpILdjunT2G6p9fR21hwynVwl9FOI8aJDinTP2msfFxuseke6Q36Cubg6HzEvMToNrV5ZfMO-UwOBvtY8MvrfUJ-_5zfzS6aq-tfl7Ozq8YJgKlRTguUrtXtIJVnCvuOOc4VwGB1r7WwrVALj4idssCY9aCt7ryTi74bWiZOyPd97yqnv2ssk3lI6xzrSsO11q1oWadriu9TLqdSMg5mlcNo88YwMFvxZi_eVPFmJ97ICn17rV4vRvRvyD_TNSD2gVK_4hLz_93v1L4Ax6qP9g</recordid><startdate>20230301</startdate><enddate>20230301</enddate><creator>Palnizky Soffer, Gili</creator><creator>Schnapp, Zeev</creator><creator>Miroluz, Dana</creator><creator>Rimon, Ayelet</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><orcidid>https://orcid.org/0000-0001-9706-5721</orcidid></search><sort><creationdate>20230301</creationdate><title>Diagnosis of Serious Conditions Delayed in Association with Ondansetron Treatment for Vomiting in the Pediatric Emergency Department</title><author>Palnizky Soffer, Gili ; Schnapp, Zeev ; Miroluz, Dana ; Rimon, Ayelet</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c300t-6c73e5c474f56d16e981c22600fa79773a436bdeee86a011ad07a78dc5b98f413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Abdomen</topic><topic>Antiemetics</topic><topic>Antiemetics - therapeutic use</topic><topic>Child</topic><topic>Children & youth</topic><topic>Emergency medical care</topic><topic>Emergency Service, Hospital</topic><topic>Gastroenteritis</topic><topic>Hospitalization</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Intestinal obstruction</topic><topic>Medical records</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meningitis</topic><topic>Ondansetron - adverse effects</topic><topic>Original Research Article</topic><topic>Ovaries</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Pharmacotherapy</topic><topic>Physicians</topic><topic>Pneumonia</topic><topic>Regression analysis</topic><topic>Retrospective Studies</topic><topic>Risk factors</topic><topic>Vomiting</topic><topic>Vomiting - drug therapy</topic><topic>Vomiting - etiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Palnizky Soffer, Gili</creatorcontrib><creatorcontrib>Schnapp, Zeev</creatorcontrib><creatorcontrib>Miroluz, Dana</creatorcontrib><creatorcontrib>Rimon, Ayelet</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Paediatric drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Palnizky Soffer, Gili</au><au>Schnapp, Zeev</au><au>Miroluz, Dana</au><au>Rimon, Ayelet</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnosis of Serious Conditions Delayed in Association with Ondansetron Treatment for Vomiting in the Pediatric Emergency Department</atitle><jtitle>Paediatric drugs</jtitle><stitle>Pediatr Drugs</stitle><addtitle>Paediatr Drugs</addtitle><date>2023-03-01</date><risdate>2023</risdate><volume>25</volume><issue>2</issue><spage>233</spage><epage>238</epage><pages>233-238</pages><issn>1174-5878</issn><eissn>1179-2019</eissn><abstract>Objectives
We evaluated the characteristics and sought risk factors for hospitalization in children who return to the emergency department within 7 days of discharge after oral or intravenous ondansetron treatment for vomiting. The secondary aim was to determine whether the diagnosis of any serious condition had been delayed as the result of discharge after ondansetron treatment.
Methods
This retrospective analysis of the medical records of children who had been treated for vomiting with ondansetron in a tertiary care pediatric emergency department and revisited the emergency department within 7 days was performed between 2017 and 2019. We compared demographic and clinical features as well as management between hospitalized and discharged patients, focusing upon potentially delayed diagnoses of serious conditions.
Results
Fifty of the 89 ondansetron-treated children (56.2%) who revisited the emergency department were discharged home after their second emergency department visit and the remaining 39 (43.8%) were hospitalized. No parameter of the management of the first visit was predictive of the outcome of the revisit. Five revisit patients (5.6%) were newly diagnosed with a serious condition, with intussusception and ovarian torsion being the most substantial time-sensitive delays (the other diagnoses were pneumonia and aseptic meningitis).
Conclusions
Physicians assessing patients who had been treated with ondansetron as supportive care for vomiting at an earlier visit to the pediatric emergency department should consider alternative diagnoses despite initial clinical improvement. No definitive risk factor for readmission was identified, but a high level of alertness to a possible meningeal or acute abdominal source is imperative.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>36696025</pmid><doi>10.1007/s40272-022-00556-5</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-9706-5721</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1174-5878 |
ispartof | Paediatric drugs, 2023-03, Vol.25 (2), p.233-238 |
issn | 1174-5878 1179-2019 |
language | eng |
recordid | cdi_proquest_journals_2777434187 |
source | MEDLINE; SpringerNature Journals |
subjects | Abdomen Antiemetics Antiemetics - therapeutic use Child Children & youth Emergency medical care Emergency Service, Hospital Gastroenteritis Hospitalization Hospitals Humans Internal Medicine Intestinal obstruction Medical records Medicine Medicine & Public Health Meningitis Ondansetron - adverse effects Original Research Article Ovaries Patients Pediatrics Pharmacotherapy Physicians Pneumonia Regression analysis Retrospective Studies Risk factors Vomiting Vomiting - drug therapy Vomiting - etiology |
title | Diagnosis of Serious Conditions Delayed in Association with Ondansetron Treatment for Vomiting in the Pediatric Emergency Department |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T04%3A18%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnosis%20of%20Serious%20Conditions%20Delayed%20in%20Association%20with%20Ondansetron%20Treatment%20for%20Vomiting%20in%20the%20Pediatric%20Emergency%20Department&rft.jtitle=Paediatric%20drugs&rft.au=Palnizky%20Soffer,%20Gili&rft.date=2023-03-01&rft.volume=25&rft.issue=2&rft.spage=233&rft.epage=238&rft.pages=233-238&rft.issn=1174-5878&rft.eissn=1179-2019&rft_id=info:doi/10.1007/s40272-022-00556-5&rft_dat=%3Cproquest_cross%3E2777434187%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2777434187&rft_id=info:pmid/36696025&rfr_iscdi=true |